Xentuzumab
Based on 1 publication(s) in Google Scholar
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.71%
- CAS No.: 1417158-65-6
- Masse moléculaire:143.7 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99294
GanitumabAnti-IGF1R Antibody -
HY-P99165
TeprotumumabIGF-1R Inhibitor -
HY-P99197
FigitumumabAnti-IGF1R Antibody -
HY-P99218
RobatumumabAnti-human IGF-1R Antibody -
HY-10252
NVP-ADW742IGF-1R Inhibitor -
HY-P99284
DalotuzumabHumanized Anti-IGF1R mAb -
HY-P99867
DusigitumabIGF Antibody -
HY-15494
PicropodophyllinApoptosis Inducer -
HY-P99189
CixutumumabAnti-IGF-1R mAb -
HY-10200
BMS-754807IGF-1R/IR Inhibitor -
HY-P9917
TocilizumabIL-6R Neutralizing Antibody -
HY-115449
ChromeceptinIGF Signaling Pathway Inhibitor
Publications Citing Use of MedChemExpress (MCE) Xentuzumab
More
Activité biologique
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IGF-1 & IGF-2
In Vitro
Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner[1].
Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown[1].
Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:0.1 μM
-
Incubation Time:24 h and 48 h
-
Result:Increased in cleaved caspase 3/7 and PARP.
Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24).
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:1 μM
-
Incubation Time:24 h, 48 h, and 72 h
-
Result:Increased in cleaved caspase 3/7 and induces cell apoptosis.
Increased the sub-G1 cell population.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1]
-
Dosage:200 mg/kg
-
Administration:Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
-
Result:Resulted in significant reductions in tumor volume.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IGF-I Protein, His Tag can bind Xentuzumab. The EC50 for this effect is 9.81 ng/mL.
Chemical Information
-
CAS No. 1417158-65-6
-
Appearance Liquid
-
Masse moléculaire 143.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Xentuzumab]
-
Synonyms
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. [Abstract]2024 Jun 10;42(6):1067-1085.e11. PMID: 38759655
Protocole
-
Recombinant antibody expression and Protein A/G purification
Recombinant antibody expression produces antibody chains from cloned antibody genes in mammalian cells, commonly HEK293-derived cells, so that secreted IgG or Fc-fusion antibodies can be collected from culture supernatant. Protein A/G purification is affinity chromatography in which immobilized Protein A, Protein G, or Protein A/G binds the antibody Fc region; nonbound culture components are washed away, and bound antibody is recovered by changing buffer conditions, commonly acidic elution followed by neutralization.
Pureté et documentation
-
Fiche technique (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Xentuzumab Related Classifications
HY-P99274 Related Classifications
Powered by Bioz